A Novel Variant of KPC-179 Conferring Ceftazidime-Avibactam Resistance in a Carbapenem-Resistant Klebsiella pneumoniae Isolate
Open Access
- 1 November 2024
- journal article
- case report
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 5129-5135
Abstract
Objective: Ceftazidime-avibactam (CZA) is a novel β-lactam/β-lactamase inhibitor with activity against carbapenem-resistant Klebsiella pneumoniae (CRKP) that produce Klebsiella pneumoniae carbapenemase (KPC). In this study, we report the first cases of CZA resistance to develop during treatment of CRKP infections and identify the resistance mechanism. Methods: APB/EDTA and NG-Test CARBA5 were used to detect the production of carbapenemase, whole-genome sequencing (WGS) and conjugation experiment were used to identify potential resistance mechanisms of CZA-susceptible (HX1032) and -resistant (HX1192) K. pneumoniae isolates. Results: HX1192 K. pneumoniae was not recognized by APB/EDTA and NG-Test CARBA5 phenotypic assays, WGS revealed it carrying a novel KPC variant, KPC-179, molecular analysis highlighted a G394A mutation, and an ATC insertion at 543 in the blaKPC-2 gene, resulting in an A133T substitution and insertion of the amino acid S at Ambler position 183 in the protein sequence. Remarkably, this mutation restored susceptibility of imipenem (MIC = 0.25 mg/L). Conclusion: Our study highlights the importance of monitoring susceptibility during CZA treatment and accurately detecting KPC variants.Keywords
This publication has 25 references indexed in Scilit:
- Comparing three different phenotypic methods for accurate detection of carbapenemase-producing EnterobacteralesJournal of Infection and Chemotherapy, 2021
- Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019Journal of Antimicrobial Chemotherapy, 2020
- Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant Klebsiella pneumoniae in China: A review over the last 10 yearsJournal of Global Antimicrobial Resistance, 2020
- Emergence and Recovery of Ceftazidime-avibactam Resistance inblaKPC-33-HarboringKlebsiella pneumoniaeSequence Type 11 Isolates in ChinaClinical Infectious Diseases, 2020
- Resistance to ceftazidime–avibactam and underlying mechanismsJournal of Global Antimicrobial Resistance, 2020
- Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patientsInternational Journal of Antimicrobial Agents, 2019
- Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial InfectionsDrugs, 2018
- Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of LiteratureOpen Forum Infectious Diseases, 2017
- Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3Antimicrobial Agents and Chemotherapy, 2017
- Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?Critical Care, 2014